OBJECTIVES: The current lack of efficacy for any chemo- or molecular therapeutic in the treatment of brain metastases is thought to be due, in part, to the heterogeneous permeability of the blood-brain-barrier (BBB). Little is known about how heterogeneous permeability develops, or how it varies among individual metastases. Understanding the BBB's role in metastasis will be crucial to the development of new, more effective therapies. In this article, we developed the first magnetic resonance imaging-based strategy to detect and measure the volumes of BBB permeable and nonpermeable metastases and studied the development of altered BBB permeability in metastases in vivo, over time in a mouse model of breast cancer metastasis to the brain. MATERIALS AND METHODS: Animals bearing human experimental brain metastases of breast cancer (231-BR cells) were imaged, using 3-dimensional balanced steady-state free precession to visualize total metastases, and contrast-enhanced T1-weighted spin echo with gadopentetic acid (Gd-DTPA) to visualize which of these displayed contrast enhancement, as Gd-DTPA leakage is indicative of altered BBB permeability. RESULTS: Metastases detected 20 days after injection showed no Gd-DTPA enhancement. At day 25, 6.1% ± 6.3% (mean ± standard deviation) of metastases enhanced, and by day 30, 28.1% ± 14.2% enhanced (P < 0.05). Enhancing metastases (mid: 0.14 ± 0.18 mm, late: 0.24 ± 0.32 mm) had larger volumes than nonenhancing (mid: 0.04 ± 0.04 mm, late: 0.09 ± 0.09 mm, P < 0.05); however, there was no significant difference between the growth rates of the 2. CONCLUSIONS: A significant number of brain metastases were uniformly nonpermeable, which highlights the need for developing treatment strategies that can overcome the permeability of the BBB. The model developed herein can provide the basis for in vivo evaluation of both BBB permeable and nonpermeable metastases response to therapy.
OBJECTIVES: The current lack of efficacy for any chemo- or molecular therapeutic in the treatment of brain metastases is thought to be due, in part, to the heterogeneous permeability of the blood-brain-barrier (BBB). Little is known about how heterogeneous permeability develops, or how it varies among individual metastases. Understanding the BBB's role in metastasis will be crucial to the development of new, more effective therapies. In this article, we developed the first magnetic resonance imaging-based strategy to detect and measure the volumes of BBB permeable and nonpermeable metastases and studied the development of altered BBB permeability in metastases in vivo, over time in a mouse model of breast cancer metastasis to the brain. MATERIALS AND METHODS: Animals bearing human experimental brain metastases of breast cancer (231-BR cells) were imaged, using 3-dimensional balanced steady-state free precession to visualize total metastases, and contrast-enhanced T1-weighted spin echo with gadopentetic acid (Gd-DTPA) to visualize which of these displayed contrast enhancement, as Gd-DTPA leakage is indicative of altered BBB permeability. RESULTS:Metastases detected 20 days after injection showed no Gd-DTPA enhancement. At day 25, 6.1% ± 6.3% (mean ± standard deviation) of metastases enhanced, and by day 30, 28.1% ± 14.2% enhanced (P < 0.05). Enhancing metastases (mid: 0.14 ± 0.18 mm, late: 0.24 ± 0.32 mm) had larger volumes than nonenhancing (mid: 0.04 ± 0.04 mm, late: 0.09 ± 0.09 mm, P < 0.05); however, there was no significant difference between the growth rates of the 2. CONCLUSIONS: A significant number of brain metastases were uniformly nonpermeable, which highlights the need for developing treatment strategies that can overcome the permeability of the BBB. The model developed herein can provide the basis for in vivo evaluation of both BBB permeable and nonpermeable metastases response to therapy.
Authors: Ingo Nolte; Marc A Brockmann; Lars Gerigk; Christoph Groden; Johann Scharf Journal: Clin Neurol Neurosurg Date: 2010-01-19 Impact factor: 1.876
Authors: James J Choi; Jameel A Feshitan; Babak Baseri; Shougang Wang; Yao-Sheng Tung; Mark A Borden; Elisa E Konofagou Journal: IEEE Trans Biomed Eng Date: 2009-10-20 Impact factor: 4.538
Authors: John N Morelli; Val M Runge; Jonathon M Williams; Robert S Beissner; Michael Tweedle Journal: Invest Radiol Date: 2011-03 Impact factor: 6.016
Authors: Fancy C Thomas; Kunal Taskar; Vinay Rudraraju; Satyanarayana Goda; Helen R Thorsheim; Julie A Gaasch; Rajendar K Mittapalli; Diane Palmieri; Patricia S Steeg; Paul R Lockman; Quentin R Smith Journal: Pharm Res Date: 2009-09-23 Impact factor: 4.200
Authors: Ho-Taek Song; Elaine K Jordan; Bobbi K Lewis; Wei Liu; Justin Ganjei; Brenda Klaunberg; Daryl Despres; Diane Palmieri; Joseph A Frank Journal: J Transl Med Date: 2009-10-20 Impact factor: 5.531
Authors: Matthew D Dun; Robert J Chalkley; Sam Faulkner; Sheridan Keene; Kelly A Avery-Kiejda; Rodney J Scott; Lasse G Falkenby; Murray J Cairns; Martin R Larsen; Ralph A Bradshaw; Hubert Hondermarck Journal: Mol Cell Proteomics Date: 2015-06-03 Impact factor: 5.911
Authors: Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt Journal: Neuro Oncol Date: 2015-05 Impact factor: 12.300
Authors: Diane Palmieri; Renata Duchnowska; Stephan Woditschka; Emily Hua; Yongzhen Qian; Wojciech Biernat; Katarzyna Sosińska-Mielcarek; Brunilde Gril; Andreas M Stark; Stephen M Hewitt; David J Liewehr; Seth M Steinberg; Jacek Jassem; Patricia S Steeg Journal: Clin Cancer Res Date: 2014-03-14 Impact factor: 12.531
Authors: L Tiffany Lyle; Paul R Lockman; Chris E Adkins; Afroz Shareef Mohammad; Emily Sechrest; Emily Hua; Diane Palmieri; David J Liewehr; Seth M Steinberg; Wojciech Kloc; Ewa Izycka-Swieszewska; Renata Duchnowska; Naema Nayyar; Priscilla K Brastianos; Patricia S Steeg; Brunilde Gril Journal: Clin Cancer Res Date: 2016-05-31 Impact factor: 12.531